MRNA
Moderna, Inc.
Income statement
| USDLine, in USD | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.5B | 1.9B | 3.2B | 6.8B | 19.3B | 18.5B | 803M | 60M | 135M | 206M | 108M |
Cost of revenue | 1.82B | 0.87B | 1.46B | 4.69B | 5.42B | 2.62B | 8.0M | 0 | 0 | — | — |
| Gross profit | 707M | 1.1B | 1.8B | 2.2B | 13.8B | 15.9B | 795M | 60M | 135M | — | — |
| 2.66B | 3.13B | 4.54B | 4.85B | 3.30B | 1.99B | 1.37B | 0.50B | 0.45B | 0.41B | 0.27B | |
Other operating expenses | 0.98B | 1.02B | 1.17B | 1.55B | 1.13B | 0.57B | 0.19B | 0.11B | 94M | — | — |
| Operating income | −2.9B | −3.1B | −3.9B | −4.2B | 9.4B | 13.3B | −763M | −546M | −413M | −269M | −224M |
Non-operating income | 201M | 306M | 338M | 297M | 155M | −11M | 19M | 31M | 29M | 13M | 8.6M |
| Pretax income | −2.7B | −2.8B | −3.6B | −3.9B | 9.6B | 13.3B | −744M | −515M | −384M | −256M | −215M |
Taxes | 60M | 54M | −46M | 0.77B | 1.21B | 1.08B | 3.0M | −1.0M | 326K | −80K | 1.0M |
| Net income | −2.8B | −2.8B | −3.6B | −4.7B | 8.4B | 12.2B | −747M | −514M | −385M | −256M | −216M |
| Diluted EPS | −7.10 | −7.26 | −9.28 | −12.33 | 20.12 | 28.29 | −1.96 | −1.55 | −4.95 | −4.18 | −3.79 |
| Diluted shares | — | 389.0M | 384.0M | 382.0M | 416.0M | 431.0M | 381.0M | 331.0M | 81.1M | 64.5M | 60.7M |
| Revenue growth | — | −39.9% | −52.7% | −64.4% | +4.3% | +2,200.2% | +1,238.3% | −55.6% | −34.4% | +89.9% | — |
| Gross margin | 28.0% | 55.3% | 54.8% | 31.5% | 71.9% | 85.8% | 99.0% | 100.0% | 100.0% | — | — |
| Operating margin | −116.0% | −158.1% | −121.9% | −61.9% | 48.9% | 72.0% | −95.0% | −910.0% | −306.0% | −130.9% | −206.4% |
| Net margin | −110.5% | −145.2% | −110.0% | −68.8% | 43.4% | 66.1% | −93.0% | −856.7% | −284.8% | −124.3% | −199.5% |